[
  {
    "ts": null,
    "headline": "3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers",
    "summary": "Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.",
    "url": "https://finnhub.io/api/news?id=016c029863ceca3d956156f9ccea70c04c5fd5cec0c2a5ae73ccfb7d452ae0a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769543460,
      "headline": "3 Healthcare ETFs to Buy as Flat Medicare Rate Proposal Hits Insurers",
      "id": 138275301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Flat Medicare Advantage rate hikes hit insurers hard, but diversified healthcare ETFs may help investors weather the policy shock.",
      "url": "https://finnhub.io/api/news?id=016c029863ceca3d956156f9ccea70c04c5fd5cec0c2a5ae73ccfb7d452ae0a6"
    }
  },
  {
    "ts": null,
    "headline": "Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss",
    "summary": "Mid-stage trial data showed Roche's experimental shot delivered weight loss on par with leading obesity treatments, supporting its late-stage trial plans.",
    "url": "https://finnhub.io/api/news?id=4c49c48591b3387dfe196ea33ce10da798f17534ecafd824a1a1fdcfda855b5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769542530,
      "headline": "Roche Shares Rise After Obesity Drug Shows 18% Greater Weight Loss",
      "id": 138273945,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Mid-stage trial data showed Roche's experimental shot delivered weight loss on par with leading obesity treatments, supporting its late-stage trial plans.",
      "url": "https://finnhub.io/api/news?id=4c49c48591b3387dfe196ea33ce10da798f17534ecafd824a1a1fdcfda855b5e"
    }
  },
  {
    "ts": null,
    "headline": "1 Pharmaceutical Stock Set to Rebound in 2026",
    "summary": "Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026.",
    "url": "https://finnhub.io/api/news?id=0e6d3a1798a1887798ee271387e068d97195597ee0054b3a8326163479dd9c67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769536800,
      "headline": "1 Pharmaceutical Stock Set to Rebound in 2026",
      "id": 138273946,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026.",
      "url": "https://finnhub.io/api/news?id=0e6d3a1798a1887798ee271387e068d97195597ee0054b3a8326163479dd9c67"
    }
  },
  {
    "ts": null,
    "headline": "Up 36%, Is Eli Lilly Still a Buy?",
    "summary": "Thanks to its weight loss and diabetes products, the drug company has seen its shares soar.",
    "url": "https://finnhub.io/api/news?id=604e1c6722abb1f8de4e0405858714903bfb7d3a467e1f64c7a0074410be0950",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769530920,
      "headline": "Up 36%, Is Eli Lilly Still a Buy?",
      "id": 138272438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Thanks to its weight loss and diabetes products, the drug company has seen its shares soar.",
      "url": "https://finnhub.io/api/news?id=604e1c6722abb1f8de4e0405858714903bfb7d3a467e1f64c7a0074410be0950"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?",
    "summary": "NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.",
    "url": "https://finnhub.io/api/news?id=cb4d5583ab87ee1f7d7eeca3b6d66e6d6180911a4a15b84c5c70db2cf35b852d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769524860,
      "headline": "Novo Nordisk vs. Viking: Which Obesity Drug Stock is the Safer Bet?",
      "id": 138272439,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO and VKTX face rising competition and setbacks as investors weigh scale, pipelines and execution risks in the crowded obesity drug race.",
      "url": "https://finnhub.io/api/news?id=cb4d5583ab87ee1f7d7eeca3b6d66e6d6180911a4a15b84c5c70db2cf35b852d"
    }
  },
  {
    "ts": null,
    "headline": "Where Will Eli Lilly Be in 10 Years?",
    "summary": "Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.",
    "url": "https://finnhub.io/api/news?id=fd2c132702eb9a713807372b571d3a39a54a37e55b74bc02b5d946e0ec3369af",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769524020,
      "headline": "Where Will Eli Lilly Be in 10 Years?",
      "id": 138270917,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever.",
      "url": "https://finnhub.io/api/news?id=fd2c132702eb9a713807372b571d3a39a54a37e55b74bc02b5d946e0ec3369af"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finnhub.io/api/news?id=53bb20c2fba67a5cd953fc7189235fc6af8f90775fe372ebb7c52f084def4074",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769522405,
      "headline": "Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 138270918,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
      "url": "https://finnhub.io/api/news?id=53bb20c2fba67a5cd953fc7189235fc6af8f90775fe372ebb7c52f084def4074"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best US stocks to buy and hold in 2026. On January 20, Eli Lilly received FDA Breakthrough Therapy designation for sofetabart mipitecan. This status applies to the treatment of adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer whose disease has progressed despite prior therapies. […]",
    "url": "https://finnhub.io/api/news?id=2414080265dd3c065166ab8d172eba104f2d9ead2108d3095c7a97a151e514e1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769521132,
      "headline": "Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth",
      "id": 138269967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the best US stocks to buy and hold in 2026. On January 20, Eli Lilly received FDA Breakthrough Therapy designation for sofetabart mipitecan. This status applies to the treatment of adults with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer whose disease has progressed despite prior therapies. […]",
      "url": "https://finnhub.io/api/news?id=2414080265dd3c065166ab8d172eba104f2d9ead2108d3095c7a97a151e514e1"
    }
  },
  {
    "ts": null,
    "headline": "Roche: Important De-Risking Of CT-388 In Obesity, Petrelintide Is Next",
    "summary": "Rocheâs CT-388 phase 2 obesity results show 22.5% weight loss and solid tolerability vs tirzepatideâplus whatâs next for petrelintide. Read the latest analysis on the stock here.",
    "url": "https://finnhub.io/api/news?id=667f833a7a85bd22c5dfac03be083c08a4913c3c76c61d7be20ebce7603dd05e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769519315,
      "headline": "Roche: Important De-Risking Of CT-388 In Obesity, Petrelintide Is Next",
      "id": 138272960,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2247616008/image_2247616008.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Rocheâs CT-388 phase 2 obesity results show 22.5% weight loss and solid tolerability vs tirzepatideâplus whatâs next for petrelintide. Read the latest analysis on the stock here.",
      "url": "https://finnhub.io/api/news?id=667f833a7a85bd22c5dfac03be083c08a4913c3c76c61d7be20ebce7603dd05e"
    }
  },
  {
    "ts": null,
    "headline": "Roche, trailing in obesity, showcases new data for GLP-1 shot",
    "summary": "A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.",
    "url": "https://finnhub.io/api/news?id=a8ec1c78ea343242d4bcaf4a404d9135ecdf01ad8497f2ca2cb1b403795d64e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769513460,
      "headline": "Roche, trailing in obesity, showcases new data for GLP-1 shot",
      "id": 138272440,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.",
      "url": "https://finnhub.io/api/news?id=a8ec1c78ea343242d4bcaf4a404d9135ecdf01ad8497f2ca2cb1b403795d64e9"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer's top 10 things to watch in the stock market Tuesday",
    "summary": "The S&P 500 was headed for a slightly higher open this morning ahead of Big Tech earnings.",
    "url": "https://finnhub.io/api/news?id=19d61e0749bd0ce0587bc1c3eca2f1d3c3d6af80688fb58ec822af4c238e4522",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769504436,
      "headline": "Jim Cramer's top 10 things to watch in the stock market Tuesday",
      "id": 138271760,
      "image": "https://image.cnbcfm.com/api/v1/image/108249640-1767822038885-gettyimages-2254513989-ALASKA_AIRLINES_BOEING.jpeg?v=1767822332&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The S&P 500 was headed for a slightly higher open this morning ahead of Big Tech earnings.",
      "url": "https://finnhub.io/api/news?id=19d61e0749bd0ce0587bc1c3eca2f1d3c3d6af80688fb58ec822af4c238e4522"
    }
  },
  {
    "ts": null,
    "headline": "2 Profitable Stocks to Own for Decades and 1 Facing Headwinds",
    "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
    "url": "https://finnhub.io/api/news?id=34bdffe000f48add7e362bd3160d01672ed1a8424cd3f0343b0160035af6f809",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769488519,
      "headline": "2 Profitable Stocks to Own for Decades and 1 Facing Headwinds",
      "id": 138269256,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.",
      "url": "https://finnhub.io/api/news?id=34bdffe000f48add7e362bd3160d01672ed1a8424cd3f0343b0160035af6f809"
    }
  }
]